This review discusses the role of immunosuppressive therapy in inflammatory cardiomyopathy and aims to define biological markers for identifying suitable candidates.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for biomarker-guided immunosuppression in inflammatory cardiomyopathy; prospective trials needed before clinical adoption.
The role of immunosuppressive treatment in inflammatory cardiomyopathy is still controversial. Nevertheless, it is recommended in patients with eosinophilic myocarditis, granulomatous myocarditis, giant-cell myocarditis and lymphocytic myocarditis associated with connective tissue diseases or with rejection of a transplanted heart. There is growing evidence that some patients with idiopathic active myocarditis and cardiac dysfunction may benefit from immunosuppression. In the present review we define, through analysis of recent reports and the results of our own studies, the biological markers of candidates for immunosuppression.
No takes yet. Share an insight, caveat, or question.
Andrea Frustaci (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: